Pleurodynia Treatment Market Size, Share, Trends, Growth 2030

Pleurodynia Treatment Industry Prospective:

The global pleurodynia treatment market size was worth around USD 128.57 million in 2022 and is predicted to grow to around USD 191.58 million by 2030 with a compound annual growth rate (CAGR) of roughly 5.28% between 2023 and 2030.

The report analyzes the global pleurodynia treatment market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the pleurodynia treatment market.

Request Free Sample

Pleurodynia Treatment Market: Overview

Pleurodynia is also known as Bornholm disease and is categorized by the occurrence of sudden and severe abdominal and chest pain. Currently, the disease does not have any specific treatment plan that can effectively treat the condition from the root. The existing standard of care requires symptom management and pain relief treatment with suggestions for resting. In recent times, the industry has witnessed tremendous interest from the research and medical community in the development of efficient treatments for pleurodynia leading to higher investments in the industry.

The fraternity runs with the aid of pharmaceutical companies and research groups that are constantly working to develop new drugs or therapies that can eliminate or reduce the associated symptoms of the condition. The treatment plan may include antiviral drugs, pain relief medications, or other therapies that target the underlying cause of the disease. Although the pleurodynia treatment industry is in its early stages, the stakeholders can expect steady growth during the forecast period.

Key Insights: 

• As per the analysis shared by our research analyst, the global pleurodynia treatment market is estimated to grow annually at a CAGR of around 5.28% over the forecast period (2023-2030)
• In terms of revenue, the global pleurodynia treatment market size was valued at around USD 128.57 million in 2022 and is projected to reach USD 191.58 million, by 2030.
• The pleurodynia treatment market is projected to grow at a significant rate due to the growing prevalence of the condition
• Based on symptoms segmentation, chest pain was predicted to show maximum market share in the year 2022
• Based on causes segmentation, Coxsackievirus B was the leading cause in 2022
• On the basis of region, North America was the leading revenue generator in 2022

Request Free Sample

Pleurodynia Treatment Market: Growth Drivers

Growing prevalence of the condition to propel market growth

The global pleurodynia treatment market is projected to witness high growth owing to the increasing number of pleurodynia cases across the globe. This has led to increased demand for effective treatment and medicines. However, the industry, currently, offers only pain and symptom management therapies or drugs and does not have an accurate cure for the condition. In 2019, the Centers for Disease Control and Prevention (CDC) report stated that the US witnessed more than 1,153 reported cases of the condition.

The condition is a viral infection and is caused by an enterovirus that generally impacts the gastrointestinal tract and respiratory system. Symptoms of the condition may either appear suddenly or take several days or a week. Some of the most common symptoms include sore throat and cough, headache and fatigue, fever and chills, and muscle soreness to name a few. The condition is also contagious which means that it can easily spread through close contact or surface contact such as toys and doorknobs. As the rate of cases registered under the condition is growing steadily, the industry may witness high demand.

Pleurodynia Treatment Market: Restraints

Absence of concrete diagnosis to restrict market expansion

The global market is fairly in its early stages and it currently lacks the presence of concrete diagnostic tools that can accurately detect the condition. Since the symptoms of the condition are similar to many other conditions like Covid-19 or general fatigue, it is difficult for healthcare professionals to accurately diagnose the condition and requires the use of elimination methods. Furthermore, since the chest pain associated with pleurodynia is extremely intense, it may be confused with cardiac arrest or some other serious medical condition. These factors could act as growth restraints in the pleurodynia treatment industry.

Pleurodynia Treatment Market: Opportunities

Growing investment toward novel therapies to prove growth opportunities

The growing rate of investment toward the development of novel therapies could work in the favor of the global pleurodynia treatment market size. Novel therapies are innovative and new treatment approaches that differ from traditional methods of treatment. It consists of using drugs, technologies, or treatment modalities that offer improved outcomes for patients. Pleurodynia-treating novel therapies may involve researching new antiviral drugs, immunotherapies, or gene therapies.

Pleurodynia Treatment Market: Challenges

Regulatory challenges to restrict market expansion

The global pleurodynia treatment industry players may face certain challenges against projected growth owing to the increasingly stricter regulations surrounding the trial and commercial availability of new pleurodynia treatment drugs and therapies. The currently existing processes are extremely time-consuming and expensive leading to fewer players in the industry thus causing a large segment of the potential market to remain unexplored.

Pleurodynia Treatment Market: Segmentation

The global pleurodynia treatment market is segmented based on causes, complications, symptoms, and region.

Based on causes, the global market segments are Coxsackievirus B, Coxsackievirus A, and echovirus. In 2022, the industry witnessed the highest growth in the Coxsackievirus B segment since it is considered the largest cause of the condition. Various studies have indicated that more than 90% of the cases of pleurodynia are caused by Coxsackievirus B while the rest of the two reasons remain relatively low in terms of leading cause. The virus is a member of the enterovirus family and exists alongside Coxsackievirus A and Echovirus. It can be easily transmitted through close contact with an infected patient or from contaminated food or water, and surfaces. The infected patient may suffer from various symptoms including fever, headache, muscle aches, and respiratory concerns.

Based on complications, the pleurodynia treatment industry divisions are meningitis, tachycardia, hepatitis, pericarditis, myocarditis, and orchitis.

Based on symptoms, the global market divisions are chest pain, cough, fever, sore throat, headache, and muscular aches & pain. The most common symptom associated with the condition is the sudden onset of stabbing chest pain which generally occurs on one side of the chest. It may also affect other areas like the abdomen, back, or shoulder. In case the patient coughs, deep breathes, or moves, the pain may worsen. It can also last for several days. However, it is difficult to define only certain symptoms since they may vary from one patient to another. As per the Centers for Medicare and Medicaid Services (CMS), the total national healthcare expenditure in the US was $3.8 trillion in 2019.

Recent Developments:

• In January 2023, verywellhealth, an online award-winning site that provides fact-based and credible information on various aspects of health-related conditions, claimed that although there is no specific treatment for the condition, patients can use nonsteroidal anti-inflammatory drugs like ibuprofen (Advil) to reduce pleurodynia-related pain. They also suggested that the application of warm packs on the affected area may also help relieve pain
• In April 2022, a study published on the Frontiers site claimed that ethyl 3-hydroxy hexanoate (EHX) which is a volatile compound found in food additives and fruits can be a potential compound working against Coxsackievirus B infections. The study also suggested that the use of EHX can be considered a safe therapeutic option during the treatment process

Pleurodynia Treatment Market: Report Scope

Pleurodynia Treatment Market: Regional Analysis

North America to lead with the highest growth rate

The global pleurodynia treatment market is expected to witness the highest growth rate in North America with the US acting as the largest shareholder. The regional growth is mainly due to the robust healthcare infrastructure of the country along with its consistency toward achieving better and effective developments in the sector.

Request Free Sample

The US is home to some of the largest pharmaceutical companies for instance Pfizer and Johnson and Johnson to name a few. These companies have managed to dominate the global pharmaceutical sector owing to growing investments toward drug development and innovation of new and effective therapies, along with a growing rate of drugs being pushed for clinical trials. In African countries, the growth may be slow due to a lack of research and medical infrastructure along with the absence of skilled professionals that can accurately diagnose and treat the condition.

Pleurodynia Treatment Market: Competitive Analysis

The global pleurodynia treatment market is led by players like:

• Roche Holding AG
• Gilead Sciences
• AbbVie
• GlaxoSmithKline
• Bristol Myers Squibb
• Johnson & Johnson
• Boehringer Ingelheim
• Pfizer
• Novartis
• Takeda Pharmaceuticals
• Merck & Co.
• Bayer
• Teva Pharmaceutical Industries
• AstraZeneca
• Amgen
• Eli Lilly and Company
• Sanofi
• Daiichi Sankyo
• Astellas Pharma.

The global pleurodynia treatment market is segmented as follows:

By Causes

• Coxsackievirus B
• Coxsackievirus A
• Echovirus

By Complications

• Meningitis
• Tachycardia
• Hepatitis
• Pericarditis
• Myocarditis
• Orchitis

By Symptoms

• Chest Pain
• Cough
• Fever
• Sore Throat
• Headache
• Muscular Aches & Pains

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa